Sign In
Buy MDGL
$512.88
+7.13 (+1.41%)
At Close: Jun 22, 2026
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday
06:54pm, Tuesday, 06'th Jan 2026
The bull case wasn't helped by an analyst's recommendation downgrade. That pundit now feels the biotech's shares only rate a hold.
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead
04:45pm, Monday, 05'th Jan 2026
Nektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved. Madrigal Pharmaceuticals is generating strong revenue from a medicine with significant prospects.
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data
08:20am, Monday, 05'th Jan 2026
Madrigal Pharmaceuticals maintains a "Strong Buy" rating, driven by Rezdiffra's FDA approval for F2-F3 MASH and robust sales momentum. MDGL is expanding Rezdiffra's reach, targeting F4 compensated MAS
Head to Head Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. Metagenomi (NASDAQ:MGX)
01:39am, Friday, 02'nd Jan 2026
Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and Metagenomi (NASDAQ: MGX - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies b
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of “Moderate Buy” by Brokerages
01:28am, Tuesday, 23'rd Dec 2025
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen analysts that are covering the firm, Marketbeat.com reports. One
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 18'th Dec 2025
CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 15'th Dec 2025
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
05:05pm, Tuesday, 09'th Dec 2025
Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 04'th Dec 2025
CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal (MDGL) Up 21.9% Since Last Earnings Report: Can It Continue?
12:37pm, Thursday, 04'th Dec 2025
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Ameritas Investment Partners Inc.
03:58am, Saturday, 29'th Nov 2025
Ameritas Investment Partners Inc. lessened its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 6.1% during the second quarter, according to the company in its most recent 13F fi
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 1-Year High on Analyst Upgrade
01:20am, Tuesday, 25'th Nov 2025
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL - Get Free Report)'s stock price reached a new 52-week high on Monday after HC Wainwright raised their price target on the stock from $568.00 to $620.00. H
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 20'th Nov 2025
CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript
02:43pm, Thursday, 20'th Nov 2025
Madrigal Pharmaceuticals, Inc. ( MDGL ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:30 AM EST Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
08:00am, Monday, 17'th Nov 2025
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor confer
